Allojenik Hematopoietik Kök Hücre Transplantasyonunda Hazırlık Rejimleri
Öz
Anahtar Kelimeler
Hazırlık rejimleri, Allojenik, Hematopoetik kök hücre transplantasyonu
Kaynakça
- Thomas et al. A history of bone marrow transplantation. In Thomas' Hematopoietic Cell Transplantation, 4 th Edition (Eds FR Appelbaum, SJ Forman, RS Negrin, KG Blume):3-7. West Sussex, UK, Wiley-Blackwell, 2009.
- Gratwohl A, Carreras E. Principles of Conditioning. In: The EBMT Handbook. Haematopoietic Stem Cell Transplantation. 6 th Edition (Eds J Apperley, E Carreras, E Gluckman, T Masszi):122-37.Genoa, Italia, Forum Service, 2012.
- Bensinger WI. High-dose preparatory regimens. In Thomas' Hematopoietic Cell Transplantation, 4th Edition (Eds FR Appelbaum, SJ Forman, RS Negrin, KG Blume):316-32. West Sussex, UK, Wiley-Blackwell, 2009.
- Young JYC, Schultheiss T. Radiotherapeutic principles of hematopoietic cell transplantation. In Thomas' Hematopoietic Cell Transplantation, 4th Edition (Eds FR Appelbaum, SJ Forman, RS Negrin, KG Blume):333-50. West Sussex, UK, Wiley-Blackwell, 2009.
- Blaise D, Vey N, Faucher C, Mohty M. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2007; 92:533-41.
- Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum: report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009; 15:367-9.
- Cantoni N, Gerull S, Heim D, Halter J, Bucher C, Buser A et al. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011; 46:344-9.
- Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002; 8:493-500.
